Acurx Pharmaceuticals to Discuss Q2 2024 Financials and Business Update on Aug 9, 2024

STATEN ISLAND, N.Y., July 16, 2024 -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a clinical-stage biopharmaceutical company specializing in the development of novel antibiotics for hard-to-treat bacterial infections, announced that it will release its second quarter 2024 financial results on Friday, August 9, 2024, at 8:00 am ET, just before the opening of the U.S. financial markets.

The conference call to discuss these results, as well as to provide a business update, will be hosted by David P. Luci, President and CEO, and Robert G. Shawah, Chief Financial Officer.

About Ibezapolstat

Ibezapolstat is Acurx Pharmaceuticals' primary antibiotic candidate, which is preparing for international Phase 3 clinical trials to treat patients suffering from Clostridioides difficile Infection (CDI). This novel antibiotic is administered orally and is being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first in a new class of DNA polymerase IIIC inhibitors aimed at combating bacterial infections. The unique activity spectrum of Ibezapolstat targets C. difficile while sparing other important Firmicutes and Actinobacteria phyla, which seems to help in maintaining a healthy gut microbiome.

In June 2018, the U.S. Food and Drug Administration (FDA) designated Ibezapolstat as a Qualified Infectious Disease Product (QIDP) for treating CDI, making it eligible for incentives under the Generating New Antibiotic Incentives Now (GAIN) Act. Additionally, in January 2019, the FDA granted "Fast Track" designation to Ibezapolstat for the treatment of CDI. The Centers for Disease Control and Prevention (CDC) has classified C. difficile as an urgent threat, underscoring the need for innovative antibiotics to treat this infection.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a late-stage biopharmaceutical firm focused on developing a novel class of small molecule antibiotics designed to address difficult-to-treat bacterial infections. The company's strategy involves developing antibiotic candidates that possess a Gram-positive selective spectrum (GPSS®), which inhibits the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC). This inhibition hinders DNA replication, resulting in the death of Gram-positive bacterial cells. Acurx's research and development pipeline includes antibiotic candidates targeting Gram-positive pathogens such as Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and drug-resistant Streptococcus pneumoniae (DRSP).

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!